IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
RMDL: Classification of Parkinson's disease by nature-inspired Algorithm
Antidiabetic activity (In vitro alpha amylase inhibitory) of ethanol extract of Carissa carandas Linn. roots.
Six sigma: an embellished exploration in the field of pharmaceutical industry
The effect of Sida acuta on bacterial enzymes in azoxymethane-induced experimental colon cancer
Premature ageing in children: a rare genetic disorder called progeria.
Stress, Depression & Gut Microbiota: The Gut-Brain Axis Regulation
Zinc oxide nanoparticles and antibiotics mediated combinatorial approach to enhance antibacterial potential
Quality of life and associated factors among students in Jambi Province, Indonesia
Novel method for simultaneous determination of spiramycin and metronidazole in pharmaceutical dosage form by UV-visible absorption spectrophotometry
The Influence of Physicians Social Capital on Patients Satisfaction
1234
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
A prospective observational study of probiotics in chronic kidney disease.

Author: J. KIRUBAKARAN, V. HEMANTH KUMAR, CH. NEELIMA PRIYA, Y. RAMA PRIYANKA , N. SATHYANARAYANA, M.D. DHANARAJU
Abstract: Chronic kidney disease is a prominent disease that is commonly observed in elderly patients but it may also observe in young adults of age between 19 to 40 years. When there is a progressive loss of kidney function, the toxins accumulate in most of the vital organs of the body which leads to inflammation and eventually, organ damage. Serum creatinine, blood urea nitrogen, uric acids are some of the uremic toxins and also include p-cresol sulfate and indoxyl sulfate. Our study is to find out the effectiveness of lactobacillus which is commercially available at low cost, by comparing with the standard recommended strains of probiotics which are high in cost. The study was conducted for about 6 months where patients were divided into two groups. One group was prescribed with standard strains and another with commercially lactobacillus. Parameters were compared before and after the treatment period. The obtained data were analysed by using the statistical method. About 100 patients were included in the study where 84 patients had completed the study successfully in which 62 were male and 22 were female from the age group of 40-70. The mean age of patients in probio-1 is 62.5 ±22.5 and in probio-2 is 57.5 ±17.5. These probiotics show a significant decrease in the blood urea nitrogen and there is no declination of serum Creatinine and uric acid. When probiotics were compared based on effectiveness, the specific strains show a significant effect in decreasing the uremic toxins when compared to commercial lactobacillus strain.
Keyword: Chronic kidney disease, Probiotics, Uremic toxins, Streptococcus thermophilus, Lactobacillus acidophilus, and Bifidobacterium longum.
DOI: https://doi.org/10.31838/ijpr/2020.12.02.0006
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free